Stock CMPX COMPASS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Compass Therapeutics, Inc.

Equities

CMPX

US20454B1044

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
1 USD -16.67% Intraday chart for Compass Therapeutics, Inc. -9.09% -35.90%
05-28 Compass Therapeutics Appoints Thomas Schuetz as CEO MT
05-28 Compass Therapeutics, Inc. Announces CEO Changes CI

Evolution of the average Target Price on Compass Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

8c6e661eb5a52ca82cfc51dce5921.fNYwrdlysN28kbnVZvG4O7ckC1TD53zKnMnIT092z7Q.JoAA2r8Bg7GNw8zjULfnDflhPzqOgUuZ1IW7CjUeuPw4r3ie6z_omPbO2g~1932ecf29f9b5d7870658d4b5901ba45

Analyst Recommendations on Compass Therapeutics, Inc.

Jefferies Starts Compass Therapeutics at Buy With $8 Price Target MT
Stifel Initiates Compass Therapeutics at Buy With $9 Price Target MT
EF Hutton Initiates Compass Therapeutics at Buy With $10.30 Price Target MT
Raymond James Adjusts Price Target on Compass Therapeutics to $8 From $5, Maintains Outperform Rating MT
HC Wainwright Adjusts Compass Therapeutics' Price Target to $10 From $12, Keeps Buy Rating MT
HC Wainwright Assumes Compass Therapeutics at Buy, Price Target Set at $12 MT
SVB Leerink Adjusts Compass Therapeutics' Price Target to $11 from $9, Keeps Outperform Rating MT
Ladenburg Thalmann Initiates Compass Therapeutics at Buy With $7 Price Target MT
B. Riley Starts Compass Therapeutics at Buy with $10 PT, Says Well-Positioned to Benefit from Potential Biotech Sector Turnaround MT
Raymond James Starts Compass Therapeutics at Outperform With $5 Price Target MT
SVB Leerink Starts Compass Therapeutics at Outperform With $12 Price Target MT
Wedbush Starts Compass Therapeutics at Outperform With $8 Price Target MT
Roth Capital Initiates Compass Therapeutics at Buy Rating With $15 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1 USD
Average target price
8.833 USD
Spread / Average Target
+783.33%
High Price Target
10 USD
Spread / Highest target
+900.00%
Low Price Target
7 USD
Spread / Lowest Target
+600.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Compass Therapeutics, Inc.

Jefferies & Co.
Stifel Nicolaus
EF Hutton
Raymond James
HC Wainwright
SVB Leerink
Ladenburg Thalmann
B. Riley
Wedbush
Roth Capital Partners

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CMPX Stock
  4. Consensus Compass Therapeutics, Inc.